• 1
    Triant VA, Regan S, Lee H, et al.Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr.2010;55:615619.
  • 2
    Friis-Moller N, Reiss P, Sabin CA, et al.Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med.2007;356:17231735.
  • 3
    Mocroft A, Reiss P, Gasiorowski J, et al.Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr.2010;55:262270.
  • 4
    Iloeje UH, Yuan Y, L’italien G, et al.Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med.2005;6:3744.
  • 5
    Saves M, Chene G, Ducimetiere P, et al.Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis.2003;37:292298.
  • 6
    Riddler SA, Li X, Chu H, et al.Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med.2007;8:280287.
  • 7
    Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med.2000;160:20502056.
  • 8
    Baekken M, Os I, Sandvik L, Oektedalen O. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens.2008;26:21262133.
  • 9
    Seaberg EC, Munoz A, Lu M, et al.Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS.2005;19:953960.
  • 10
    Cattelan AM, Trevenzoli M, Sasset L, et al.Indinavir and systemic hypertension. AIDS.2001;15:805807.
  • 11
    Islam F, Wu J, Jansson J, Wilson D. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med.2012;13:45368.
  • 12
    Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone NF. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Physicians AIDS Care (Chic).2012;11:2025.
  • 13
    Manner IW, Baekken M, Oektedalen O, et al.Effect of HIV duration on ambulatory blood pressure in HIV-infected individuals with high office blood pressure. Blood Press.2010;19:188195.
  • 14
    Brenchley JM, Price DA, Schacker TW, et al.Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med.2006;12:13651371.
  • 15
    Giorgi JV, Hultin LE, McKeating JA, et al.Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis.1999;179:859870.
  • 16
    Hunt PW, Cao HL, Muzoora C, et al.Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS.2011;25:21232131.
  • 17
    Sandler NG, Wand H, Roque A, et al.Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis.2011;203:780790.
  • 18
    Jiang W, Lederman MM, Hunt P, et al.Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis.2009;199:11771185.
  • 19
    Microbial translocation independently predicts future hypertension in HIV-infected individuals. Paper #814. 19th Conference on Retroviruses and Opportunistic Infections; 2012.
  • 20
    EACS guidelines, version 6.0. Web [serial online], 2011.
  • 21
    Kelley CF, Kitchen CM, Hunt PW, et al.Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis.2009;48:787794.
  • 22
    Kaufmann GR, Furrer H, Ledergerber B, et al.Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis.2005;41:361372.
  • 23
    Robbins GK, Spritzler JG, Chan ES, et al.Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis.2009;48:350361.
  • 24
    van Lelyveld SF, Gras L, Kesselring A, et al.Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS.2012;226:465474.
  • 25
    Baker JV, Peng G, Rapkin J, et al.CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS.2008;22:841848.
  • 26
    Lewden C, Chene G, Morlat P, et al.HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr.2007;46:7277.
  • 27
    Achhra AC, Amin J, Law MG, et al.Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS.2010;24:18771886.
  • 28
    Lederman MM, Calabrese L, Funderburg NT, et al.Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis.2011;204:12171226.
  • 29
    Hunt PW, Martin JN, Sinclair E, et al.T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis.2003;187:15341543.
  • 30
    Ho JE, Scherzer R, Hecht FM, et al.The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS.2012;26:11151120.
  • 31
    Palacios R, Santos J, Garcia A, et al.Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Medicine.2006;7:1015.
  • 32
    Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS.2006;20:10191026.
  • 33
    Crane HM, Grunfeld C, Harrington RD, Kitahata MM. Lipoatrophy and lipohypertrophy are independently associated with hypertension. HIV Med.2009;10:496503.
  • 34
    Jerico C, Knobel H, Montero M, et al.Hypertension in HIV-infected patients: prevalence and related factors. Am J Hypertens.2005;18:13961401.
  • 35
    Arruda Junior ER, Lacerda HR, Moura LC, et al.Risk factors related to hypertension among patients in a cohort living with HIV/AIDS. Braz J Infect Dis.2010;14:281287.
  • 36
    Manner IW, Baekken M, Oektedalen O, Os I. Hypertension and antihypertensive treatment in HIV-infected individuals. A longitudinal cohort study. Blood Press.2012;21:31119.
  • 37
    Levey AS, Stevens LA, Schmid CH, et al.A new equation to estimate glomerular filtration rate. Ann Intern Med.2009;150:604612.
  • 38
    Klouman K, Åsberg A, Widerøe T. The blood pressure level in a Norwegian population - the significance of inheritance and lifestyle. Tidsskrift for Den norske legeforening.2012;131:11851189.
  • 39
    Fernandez S, Price P, McKinnon EJ, et al.Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function. Clin Immunol.2006;120:163170.
  • 40
    Wiedermann CJ, Kiechl S, Dunzendorfer S, et al.Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol.1999;34:19751981.
  • 41
    Biomarkers of microbial translocation and macrophage activation are associated with progression of atherosclerosis in HIV infection: ACTG NWCS 332/A5078 study. Paper #122. 19th Conference on Retroviruses and Opportunistic Infections; 2012.
  • 42
    Harrison DG, Guzik TJ, Lob HE, et al.Inflammation, immunity, and hypertension. Hypertension.2011;57:132140.
  • 43
    Dauphinee SM, Karsan A. Lipopolysaccharide signaling in endothelial cells. Lab Invest.2006;86:922.
  • 44
    Solages A, Vita JA, Thornton DJ, et al.Endothelial function in HIV-infected persons. Clin Infect Dis.2006;42:13251332.
  • 45
    Oliviero U, Bonadies G, Apuzzi V, et al.Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis.2009;204:586589.
  • 46
    Hsue PY, Lo JC, Franklin A, et al.Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation.2004;109:16031608.
  • 47
    Ho JE, Deeks SG, Hecht FM, et al.Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS.2010;24:18971905.